On November 6th Tenax Therapeutics (TENX) filed an S-1 proposing to raise $10 million in equity capital to support operations into 2020. While the funds are not needed to launch the Phase II trial for ...
25d
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 data in H2 2026. Read the full analysis here.
2018 began a new chapter for Tenax Therapeutics (TENX). In January, Tenax announced its plan to advance the development of levosimendan for Pulmonary Hypertension associated with Heart Failure and ...
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results